- Home
- BGSF vs IMA Comparison
BGSF vs IMA Comparison
Compare BGSF & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BGSF | IMA |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 66.3M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | BGSF | IMA |
|---|---|---|
| Price | $5.05 | $5.69 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 8.4K | ★ 13.4K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 36.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,310,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.26 | $3.94 |
| 52 Week High | $8.20 | $17.50 |
Technical Indicators
Market Signals| Indicator | BGSF | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 49.22 |
| Support Level | $4.97 | $5.23 |
| Resistance Level | $5.36 | $6.12 |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 43.18 | 45.33 |
Price Performance
Historical ComparisonAbout BGSF BGSF Inc.
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. The company operates in one segment of Property Management, which includes centralized support services through executive, marketing, human resources, information technology, accounting, treasury, and billing operations.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.